Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) is frequently in the news for developments related to its stabilized hypochlorous acid (HOCl) products based on patented Microcyn technology. The company issues regular updates on product launches, regulatory milestones, distribution partnerships, and financial results, giving investors and industry observers insight into how its HOCl portfolio is being deployed in wound care, eye care, oral and nasal care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants.
News coverage often highlights Sonoma’s expansion into consumer and professional markets. Recent press releases describe HOCl-based diaper rash products for infants and children launched into large U.S. retailers, hypochlorous acid-based acne products placed in retail pharmacy chains in the United Kingdom, and a Microcyn-based facial spray listed under the FDA’s Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The company also reports on collaborations such as its HOCl wound cleanser manufactured for Medline Industries, LP for distribution into U.S. hospital systems and home healthcare channels.
Regulatory and recognition updates are another key theme. Sonoma has announced successful transition of its European products to the EU Medical Device Regulation (MDR), registrations with the MHRA in the United Kingdom, and multiple seals for Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel from organizations such as the National Psoriasis Foundation and the National Rosacea Society. Financial news includes quarterly and annual results, revenue trends by region, and non-GAAP metrics such as EBITDA loss.
By following the SNOA news feed, readers can monitor how Sonoma’s HOCl-based products are progressing through new markets, how its regulatory footprint is evolving, and how these developments are reflected in reported financial performance and corporate actions.
Sonoma Pharmaceuticals (Nasdaq: SNOA) reported third fiscal quarter and nine-month results for the period ended December 31, 2025. Q3 revenue was $4.3 million, up 22% year-over-year; nine-month revenue was $14.0 million, up 33% year-over-year. Gross margin rose to 38% in Q3 versus 36% prior year.
EBITDAS loss improved by $0.4 million in Q3 and $0.9 million for the nine months. U.S. revenue growth was strong, driven by OTC sales and distributor expansion, while Latin America showed declines due to order timing.
Sonoma Pharmaceuticals (Nasdaq: SNOA) announced board and senior leadership changes effective January 28, 2026. Vanessa Jacoby joins the Board and will chair the Audit Committee; longtime director Dr. Jay Birnbaum retired. Arturo Angel was appointed Senior Vice President of Regulatory, Quality and Product Development.
Jacoby brings finance and biotech audit experience and is a licensed CPA. Angel brings 15+ years in R&D at Bausch Health and extensive formulation and product development expertise.
Sonoma Pharmaceuticals (Nasdaq: SNOA) announced on November 13, 2025 that Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned the National Rosacea Society Seal of Acceptance. The Seal identifies products clinically evaluated and found unlikely to irritate sensitive rosacea skin. Reliefacyn previously earned the National Eczema Association Seal of Acceptance and the National Psoriasis Foundation Seal of Recognition, highlighting Sonoma's Microcyn-based skincare portfolio and focus on products for chronic skin conditions.
Sonoma Pharmaceuticals (Nasdaq:SNOA) will exhibit at MEDICA 2025 in Düsseldorf, Germany, from November 17–20, 2025.
MEDICA is expected to draw about 80,000 visitors from 72 countries and over 5,000 exhibitors. Sonoma will display Microcyn® technology-based HOCl products for scar management, atopic dermatitis, acne, wound care, and eyelid infection, and aims to expand its global distributor network. Visitors can find Sonoma at booth D17/4 in Hall 16. For inquiries, contact busdev@sonomapharma.com.
Sonoma Pharmaceuticals (Nasdaq:SNOA) reported record quarterly revenue of $5.6M for Q2 fiscal 2026, a 57% increase year‑over‑year, and six‑month revenue of $9.6M, up 38% YoY. U.S. revenue rose 115% for the quarter and 86% for the six months. Gross profit was $2.1M (38% margin) for the quarter and $3.6M (37% margin) for six months. Net loss was $0.5M for the quarter and $1.8M for six months; the company reported improvements in EBITDA (quarterly EBITDA loss $0.2M, six‑month EBITDA loss $0.8M). Cash and cash equivalents were $3.0M as of September 30, 2025.
Recent commercial and regulatory milestones include Walmart rollout of diaper rash products (Aug 13, 2025), NPF seal for Reliefacyn (Aug 26, 2025), MoCRA listing and facility registration (Oct 7, 2025), and a Medline wound cleanser launch (Oct 14, 2025).
Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, on October 14, 2025.
The product will be distributed by Medline into U.S. hospital systems, home healthcare and other healthcare channels. The collaboration between Sonoma and Medline began in 2024 and pairs Sonoma's Microcyn technology with Medline's nationwide distribution to provide clinicians an advanced wound-cleansing option that aims to promote healing and reduce infection risk without harming healthy tissue.
Sonoma Pharmaceuticals (Nasdaq:SNOA) announced on October 7, 2025 that it has registered its manufacturing facility and listed a Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act (MoCRA). The MoCRA registration enables Sonoma to manufacture and commercialize Microcyn technology products as cosmetics in the U.S., expanding the company's regulatory footprint beyond its existing FDA medical device establishment registration and 510(k)-cleared portfolio.
The company said this step increases access to U.S. cosmetics and dermatology consumer markets, citing a projected U.S. skin care market near $40 billion by 2030, and positions Sonoma to pursue growth with its patented hypochlorous acid technology.
Sonoma Pharmaceuticals (Nasdaq:SNOA), a healthcare company specializing in Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference.
The virtual event will take place on September 30, 2025, featuring a webcast presentation at 2:00 p.m. ET. Management will also be available for one-on-one meetings with investors throughout the conference. The company develops products for various applications including wound care, eye care, dermatological conditions, podiatry, and animal health care.
Sonoma Pharmaceuticals (Nasdaq:SNOA), a healthcare company specializing in Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has received the National Psoriasis Foundation (NPF) Seal of Recognition for its Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel.
The product, which previously earned the National Eczema Association Seal of Acceptance, was independently reviewed by medical experts and met NPF's standards for safety, ingredient quality, and tolerability on sensitive skin. This recognition validates the product's efficacy for people with chronic skin conditions including psoriasis, eczema, and sensitive skin.
Sonoma Pharmaceuticals (Nasdaq:SNOA) has announced the launch of its HOCl-based diaper rash product in major U.S. retail channels. The antimicrobial hydrogel, based on their patented Microcyn® technology, is now available in 3,600 Walmart stores, Amazon.com, and various large grocery chains.
This launch marks Sonoma's strategic expansion into the over-the-counter consumer market, offering their stabilized hypochlorous acid (HOCl) technology directly to consumers seeking solutions for diaper rash and skin irritations. The product is being distributed through their U.S.-based distribution partner.
FAQ
What is the current stock price of Sonoma Pharmaceu (SNOA)?
What is the market cap of Sonoma Pharmaceu (SNOA)?
